Alcobra (ADHD) Appoints J.P. Morgan Banker Dr. Tomer Berkovitz As Chief Financial Officer
2/19/2014 8:55:20 AM
TEL AVIV, Israel, Feb. 19, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, Metadoxine Extended Release (MDX; MG01CI), to treat cognitive dysfunction, announced today that it has appointed Dr. Tomer Berkovitz as Chief Financial Officer, effective May 1, 2014. Dr. Berkovitz will report to Dr. Yaron Daniely, President and Chief Executive Officer, and will be responsible for all Corporate Finance and Accounting activities for Alcobra.
Help employers find you! Check out all the jobs and post your resume.
comments powered by